Selected research
Market Structure
Global Pegfilgrastim Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Pegfilgrastim Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Pegfilgrastim Injection include CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi, Amgen Inc. and Coherus BioSciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Pegfilgrastim Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pegfilgrastim Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pegfilgrastim Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pegfilgrastim Injection market size, projected growth trends, production technologies, key applications, and end-use industries.
Pegfilgrastim Injection Segment by Company
CSPC
Sandoz (Novartis)
Qilu Pharmaceutical
Mylan
Pfizer
Jiangsu Hengrui Medicine
Fresenius Kabi
Amgen Inc.
Coherus BioSciences, Inc.
Biocon Biologics Inc.
Pegfilgrastim Injection Segment by Type
Innovative Drugs
Generic Drugs
Pegfilgrastim Injection Segment by Application
Neoplastic Diseases
Blood Disorders
Others
Pegfilgrastim Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pegfilgrastim Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pegfilgrastim Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pegfilgrastim Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pegfilgrastim Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pegfilgrastim Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pegfilgrastim Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Pegfilgrastim Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Innovative Drugs
- Generic Drugs
Applications
- Neoplastic Diseases
- Blood Disorders
- Others
Companies covered
- CSPC
- Sandoz (Novartis)
- Qilu Pharmaceutical
- Mylan
- Pfizer
- Jiangsu Hengrui Medicine
- Fresenius Kabi
- Amgen Inc.
- Coherus BioSciences, Inc.
- Biocon Biologics Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pegfilgrastim Injection Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pegfilgrastim Injection Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Pegfilgrastim Injection Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Pegfilgrastim Injection Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Pegfilgrastim Injection Market Dynamics
- 2.1 Pegfilgrastim Injection Industry Trends
- 2.2 Pegfilgrastim Injection Industry Drivers
- 2.3 Pegfilgrastim Injection Industry Opportunities and Challenges
- 2.4 Pegfilgrastim Injection Industry Restraints
3 Pegfilgrastim Injection Market by Manufacturers
- 3.1 Global Pegfilgrastim Injection Revenue by Manufacturers (2021-2026)
- 3.2 Global Pegfilgrastim Injection Sales by Manufacturers (2021-2026)
- 3.3 Global Pegfilgrastim Injection Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Pegfilgrastim Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Pegfilgrastim Injection Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Pegfilgrastim Injection Manufacturers, Product Type & Application
- 3.7 Global Pegfilgrastim Injection Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Pegfilgrastim Injection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Pegfilgrastim Injection Players Market Share by Revenue in 2025
- 3.8.3 2025 Pegfilgrastim Injection Tier 1, Tier 2, and Tier 3
4 Pegfilgrastim Injection Market by Type
- 4.1 Pegfilgrastim Injection Type Introduction
- 4.1.1 Innovative Drugs
- 4.1.2 Generic Drugs
- 4.2 Global Pegfilgrastim Injection Sales by Type
- 4.2.1 Global Pegfilgrastim Injection Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pegfilgrastim Injection Sales by Type (2021-2032)
- 4.2.3 Global Pegfilgrastim Injection Sales Market Share by Type (2021-2032)
- 4.3 Global Pegfilgrastim Injection Revenue by Type
- 4.3.1 Global Pegfilgrastim Injection Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Pegfilgrastim Injection Revenue by Type (2021-2032)
- 4.3.3 Global Pegfilgrastim Injection Revenue Market Share by Type (2021-2032)
5 Pegfilgrastim Injection Market by Application
- 5.1 Pegfilgrastim Injection Application Introduction
- 5.1.1 Neoplastic Diseases
- 5.1.2 Blood Disorders
- 5.1.3 Others
- 5.2 Global Pegfilgrastim Injection Sales by Application
- 5.2.1 Global Pegfilgrastim Injection Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pegfilgrastim Injection Sales by Application (2021-2032)
- 5.2.3 Global Pegfilgrastim Injection Sales Market Share by Application (2021-2032)
- 5.3 Global Pegfilgrastim Injection Revenue by Application
- 5.3.1 Global Pegfilgrastim Injection Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Pegfilgrastim Injection Revenue by Application (2021-2032)
- 5.3.3 Global Pegfilgrastim Injection Revenue Market Share by Application (2021-2032)
6 Global Pegfilgrastim Injection Sales by Region
- 6.1 Global Pegfilgrastim Injection Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pegfilgrastim Injection Sales by Region (2021-2032)
- 6.2.1 Global Pegfilgrastim Injection Sales by Region (2021-2026)
- 6.2.2 Global Pegfilgrastim Injection Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pegfilgrastim Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Pegfilgrastim Injection Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Pegfilgrastim Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Pegfilgrastim Injection Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Pegfilgrastim Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Pegfilgrastim Injection Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Pegfilgrastim Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Pegfilgrastim Injection Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Pegfilgrastim Injection Revenue by Region
- 7.1 Global Pegfilgrastim Injection Revenue by Region
- 7.1.1 Global Pegfilgrastim Injection Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Pegfilgrastim Injection Revenue by Region (2021-2026)
- 7.1.3 Global Pegfilgrastim Injection Revenue by Region (2027-2032)
- 7.1.4 Global Pegfilgrastim Injection Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Pegfilgrastim Injection Revenue (2021-2032)
- 7.2.2 North America Pegfilgrastim Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Pegfilgrastim Injection Revenue (2021-2032)
- 7.3.2 Europe Pegfilgrastim Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Pegfilgrastim Injection Revenue (2021-2032)
- 7.4.2 Asia-Pacific Pegfilgrastim Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Pegfilgrastim Injection Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Pegfilgrastim Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSPC
- 8.1.1 CSPC Company Information
- 8.1.2 CSPC Business Overview
- 8.1.3 CSPC Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSPC Pegfilgrastim Injection Product Portfolio
- 8.1.5 CSPC Recent Developments
- 8.2 Sandoz (Novartis)
- 8.2.1 Sandoz (Novartis) Company Information
- 8.2.2 Sandoz (Novartis) Business Overview
- 8.2.3 Sandoz (Novartis) Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sandoz (Novartis) Pegfilgrastim Injection Product Portfolio
- 8.2.5 Sandoz (Novartis) Recent Developments
- 8.3 Qilu Pharmaceutical
- 8.3.1 Qilu Pharmaceutical Company Information
- 8.3.2 Qilu Pharmaceutical Business Overview
- 8.3.3 Qilu Pharmaceutical Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Qilu Pharmaceutical Pegfilgrastim Injection Product Portfolio
- 8.3.5 Qilu Pharmaceutical Recent Developments
- 8.4 Mylan
- 8.4.1 Mylan Company Information
- 8.4.2 Mylan Business Overview
- 8.4.3 Mylan Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Mylan Pegfilgrastim Injection Product Portfolio
- 8.4.5 Mylan Recent Developments
- 8.5 Pfizer
- 8.5.1 Pfizer Company Information
- 8.5.2 Pfizer Business Overview
- 8.5.3 Pfizer Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Pfizer Pegfilgrastim Injection Product Portfolio
- 8.5.5 Pfizer Recent Developments
- 8.6 Jiangsu Hengrui Medicine
- 8.6.1 Jiangsu Hengrui Medicine Company Information
- 8.6.2 Jiangsu Hengrui Medicine Business Overview
- 8.6.3 Jiangsu Hengrui Medicine Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Jiangsu Hengrui Medicine Pegfilgrastim Injection Product Portfolio
- 8.6.5 Jiangsu Hengrui Medicine Recent Developments
- 8.7 Fresenius Kabi
- 8.7.1 Fresenius Kabi Company Information
- 8.7.2 Fresenius Kabi Business Overview
- 8.7.3 Fresenius Kabi Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Fresenius Kabi Pegfilgrastim Injection Product Portfolio
- 8.7.5 Fresenius Kabi Recent Developments
- 8.8 Amgen Inc.
- 8.8.1 Amgen Inc. Company Information
- 8.8.2 Amgen Inc. Business Overview
- 8.8.3 Amgen Inc. Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Amgen Inc. Pegfilgrastim Injection Product Portfolio
- 8.8.5 Amgen Inc. Recent Developments
- 8.9 Coherus BioSciences, Inc.
- 8.9.1 Coherus BioSciences, Inc. Company Information
- 8.9.2 Coherus BioSciences, Inc. Business Overview
- 8.9.3 Coherus BioSciences, Inc. Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Coherus BioSciences, Inc. Pegfilgrastim Injection Product Portfolio
- 8.9.5 Coherus BioSciences, Inc. Recent Developments
- 8.10 Biocon Biologics Inc.
- 8.10.1 Biocon Biologics Inc. Company Information
- 8.10.2 Biocon Biologics Inc. Business Overview
- 8.10.3 Biocon Biologics Inc. Pegfilgrastim Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Biocon Biologics Inc. Pegfilgrastim Injection Product Portfolio
- 8.10.5 Biocon Biologics Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Pegfilgrastim Injection Value Chain Analysis
- 9.1.1 Pegfilgrastim Injection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Pegfilgrastim Injection Production Mode & Process
- 9.2 Pegfilgrastim Injection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Pegfilgrastim Injection Distributors
- 9.2.3 Pegfilgrastim Injection Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst